Amgen publishes Q3 2026 earnings presentation
- Amgen’s third-quarter 2026 revenue rose 8% year over year to $10.4 billion.
- Non-GAAP earnings per share increased 14% to $6.45; non-GAAP operating margin reached 47%.
- Non-GAAP research and development spending rose 11% to $2.1 billion.
- Rare disease sales grew 37%, innovative oncology sales increased 21%, and biosimilar sales rose 26%.
- Seventeen products posted double-digit sales growth; 17 products were annualizing at $1 billion or more based on quarterly sales.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.